Alexion Announces Appointment of Tanisha Carino, Ph.D., as Chief Corporate Affairs Officer

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of Tanisha Carino, Ph.D., as Executive Vice President and the company’s first Chief Corporate Affairs Officer. Dr. Carino will join Alexion on November 4, 2019 and will serve on the company’s Executive Committee. In her role, Dr. Carino will oversee the creation of a newly integrated Corporate Affairs function that encompasses Alexion’s corporate affairs activities, including high-level relations with domestic and international governments and global communications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005839/en/

(Photo: Business Wire)

“I am delighted that Tanisha will be joining Alexion and our Executive Committee. Her extensive experience advocating for the development of medicines for rare diseases and the rare disease community will be instrumental as Alexion enters our next chapter, with our significantly expanded and diversified pipeline that provides the opportunity to serve more patients than ever before,” said Ludwig Hantson, Ph.D., Chief Executive Officer at Alexion. “The creation of this new role represents our continued commitment to elevating our leadership in rare disease and our desire for enhanced engagement with governments and other stakeholders to support the role transformative science brings to people affected by rare diseases.”

“For nearly 30 years, Alexion has been at the forefront of developing medicines for rare diseases,” said Dr. Carino. “I am excited to join a company with such an unwavering focus on patients and look forward to helping advance the company’s mission of transforming the lives of people with rare diseases.”

Throughout her distinguished career, Dr. Carino has been at the forefront of collaborative efforts to promote policies, research, and business practices supporting the fight against disease and improving the lives of patients. Prior to joining Alexion, Dr. Carino served as the Executive Director of FasterCures, a Center of the Milken Institute, whose mission is to put patients in the center of the healthcare system, break down unnecessary barriers to innovation, and accelerate biomedical research. Prior to leading FasterCures, Dr. Carino was an executive at GlaxoSmithKline where she led the United States policy function and prior to that, spent over a decade with Avalere Health, a strategic advisory services organization, where she worked with senior leaders of life sciences companies to maximize opportunities and mitigate challenges related to biomedical research and patient access. Dr. Carino is a Fulbright Fellow, earned her Ph.D. in health policy from Johns Hopkins University, and is associate faculty at the Johns Hopkins Bloomberg School of Public Health.

About Alexion
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS), anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition, the company is developing several mid-to-late-stage therapies, including a second complement inhibitor, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases as well as several early-stage therapies, including one for light chain (AL) amyloidosis and a second anti-FcRn therapy. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has been named to the Forbes’ list of the World’s Most Innovative Companies seven years in a row and is headquartered in Boston, Massachusetts’ Innovation District. The company also has offices around the globe and serves patients in more than 50 countries. This press release and further information about Alexion can be found at: www.alexion.com.

[ALXN-G]

Forward-Looking Statement
This press release contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Alexion, including statements related to: Alexion’s commitment to elevating its leadership in rare disease and its desire for enhanced partnership with governments and other stakeholders to support the role transformative science brings to people affected by rare diseases; Alexion’s significantly expanded and diversified pipeline provides the opportunity to serve more patients than ever before; and Alexion’s ambition to be a global leader. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ materially from those expected by these forward looking statements, including for example: Alexion may be unable to elevate its leadership in rare disease due to, among other reasons, the continued reliance on complement therapies (Soliris and Ultomiris) for much of its revenues and the inability to expand its product pipeline or obtain regulatory approval and commercialize products currently in the pipeline; Alexion’s plan for enhanced engagement with governments and other stakeholders to support the role transformative science brings to people affected by rare diseases may not be realized as a result of, among other factors, government policies regarding health care and reimbursement are shifting; ; the anticipated benefits of our products and product candidates may not be realized; the possibility that results of clinical trials are not predictive of safety and efficacy and potency of our products (or we fail to adequately operate or manage our clinical trials) which could cause us to discontinue sales of the product (or halt trials, delay or prevent us from making regulatory approval filings or result in denial of approval of our product candidates); unexpected delays in clinical trials; unexpected concerns regarding products and product candidates that may arise from additional data or analysis obtained during clinical trials or obtained once used by patients following product approval; future product improvements may not be realized due to expense or feasibility or other factors; inability to timely submit (or failure to submit) future applications for regulatory approval for our products and product candidates; inability to timely initiate (or failure to initiate) and complete future clinical trials due to safety issues, IRB decisions, CMC-related issues, expense or unfavorable results from earlier trials (among other reasons); future competition from biosimilars and novel products; decisions of regulatory authorities regarding the adequacy of our research, marketing approval or material limitations on the marketing of our products; delays or failure of product candidates to obtain regulatory approval; delays or the inability to launch product candidates due to regulatory restrictions, anticipated expense or other matters; interruptions or failures in the manufacture and supply of our products and our product candidates; failure to satisfactorily address matters raised by regulatory agencies regarding products and product candidates; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; inability to complete acquisitions or grow the product pipeline through acquisitions (including due to failure to obtain antitrust approvals); the possibility that current rates of adoption of our products are not sustained; the adequacy of our pharmacovigilance and drug safety reporting processes; failure to protect and enforce our data, intellectual property and proprietary rights and the risks and uncertainties relating to intellectual property claims, lawsuits and challenges against us (including intellectual property lawsuits relating to ULTOMIRIS brought by third parties and inter partes review petitions initiated by third parties); the risk that third party payors (including governmental agencies) will not reimburse or continue to reimburse for the use of our products at acceptable rates or at all; failure to realize the benefits and potential of investments, collaborations, licenses and acquisitions; the possibility that expected tax benefits will not be realized; delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement; uncertainties surrounding legal proceedings, company investigations and government investigations, including investigations of Alexion by the U.S. Securities and Exchange Commission (SEC) and U.S. Department of Justice; the risk that estimates regarding the number of patients with PNH, aHUS, gMG, NMOSD, HPP and LAL-D and other indications we are pursuing are inaccurate; the risks of changing foreign exchange rates; risks relating to the potential effects of the Company's restructuring; risks related to the acquisition of Syntimmune and other companies and co-development efforts; and a variety of other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 and in our other filings with the SEC. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005839/en/